{"id":"NCT03976375","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","officialTitle":"A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-26","primaryCompletion":"2023-08-11","completion":"2024-08-22","firstPosted":"2019-06-06","resultsPosted":"2024-08-22","lastUpdate":"2025-08-15"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Non-Small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"]},{"type":"DRUG","name":"Docetaxel","otherNames":["TAXOTERE®"]}],"arms":[{"label":"Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"},{"label":"Lenvatinib Monotherapy","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to ~47 months","effectByArm":[{"arm":"Pembrolizumab+Lenvatinib","deltaMin":11.3,"sd":null},{"arm":"Docetaxel","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4342"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":24},"locations":{"siteCount":143,"countries":["United States","Argentina","Australia","Canada","Colombia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Portugal","Puerto Rico","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["40473109","34409776","33300372"],"seeAlso":["https://www.merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26246&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":181},"commonTop":["Diarrhoea","Asthenia","Decreased appetite","Hypertension","Fatigue"]}}